Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Phibro Animal Health (PAHC) EBITDA (2016 - 2025)

Phibro Animal Health (PAHC) has 13 years of EBITDA data on record, last reported at $50.3 million in Q4 2025.

  • For Q4 2025, EBITDA rose 814.35% year-over-year to $50.3 million; the TTM value through Dec 2025 reached $148.1 million, up 291.11%, while the annual FY2025 figure was $110.5 million, 107.19% up from the prior year.
  • EBITDA reached $50.3 million in Q4 2025 per PAHC's latest filing, up from $30.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $50.3 million in Q4 2025 and bottomed at -$7.0 million in Q4 2024.
  • Average EBITDA over 5 years is $16.7 million, with a median of $18.9 million recorded in 2021.
  • Peak YoY movement for EBITDA: soared 1521.43% in 2022, then tumbled 380.12% in 2024.
  • A 5-year view of EBITDA shows it stood at $10.8 million in 2021, then decreased by 3.47% to $10.5 million in 2022, then plummeted by 75.99% to $2.5 million in 2023, then plummeted by 380.12% to -$7.0 million in 2024, then skyrocketed by 814.35% to $50.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $50.3 million in Q4 2025, $30.5 million in Q3 2025, and $33.7 million in Q2 2025.